The massive $820M financing validates Avere's pipeline but confirms near-total dilution for existing NXTC holders. Monitor for stockholder vote on the merger and S-4 filing. The combined entity's value is now tied entirely to AVR-001's clinical execution in psoriasis and expansion into IBD/PsA.
Price Chart
Executive Summary
NextCure (NXTC) filed a 425 communication announcing an additional $500 million private placement for Avere Therapeutics, on top of the previously announced $320 million concurrent private investment, bringing total pre-closing financing to $820 million. The combined proceeds are expected to fully fund Avere's operating plan into 2029, supporting the development of AVR-001, a once-weekly oral IL-23 receptor antagonist for psoriasis. This filing confirms the reverse merger with Avere is progressing toward a second-half 2026 close, with existing NXTC shareholders retaining approximately 1.29% of the combined entity, which will trade under the ticker AVRX.
Key Financial Metrics
Key Facts
- Avere Therapeutics announced a $500 million private placement from a syndicate of leading healthcare investors, in addition to the previously announced $320 million concurrent private investment.
- Total pre-closing financing of $820 million is expected to fully fund Avere's operating plan into 2029.
- Upon closing, Avere is expected to have 449,668,672 as-converted shares outstanding.
- Existing NextCure shareholders will retain approximately 1.29% of the combined company (5,785,112 shares).
- The combined company is expected to trade on Nasdaq under the ticker symbol 'AVRX' upon deal close in the second half of 2026.
- AVR-001 is a once-weekly oral IL-23 receptor antagonist with Phase 1 data showing comparable efficacy to J&J's Icotyde (icotrokinra) in psoriasis.
- Participants in the private placement include Venrock Healthcare Capital Partners, General Atlantic, Blackstone, RTW Investments, Wellington Management, Janus Henderson Investors, and others.
Financial Impact
Existing NXTC shareholders diluted to ~1.29% ownership in combined entity valued at $250M+; $820M total financing raised for Avere
Risk Factors
- Reverse merger may not close on timeline or at all
- AVR-001 clinical data may not replicate in larger Phase 2/3 trials
- IL-23 IP landscape is crowded with potential infringement claims
- Dependence on in-licensed Hansoh program and associated milestone/royalty obligations
- Clinical data from China may not be accepted by FDA
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001104659-26-093342 |
| Document: 0001104659-26-093342-index-headers.html | 0001104659-26-093342 |
| Document: 0001104659-26-093342-index.html | 0001104659-26-093342 |
| Document: 0001104659-26-093342.txt | 0001104659-26-093342 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.72 (+5.06%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.72 (+12.50%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.72 (+15.08%) |
Aug 4, 2026 12w ago | 425 | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.72 (−1.12%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.72 (+13.62%) |
Jul 14, 2026 15w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.72 (−13.15%) |
Jul 14, 2026 15w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.72 (+13.15%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.72 (+69.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers